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Glioblastoma Multiforme (GBM) is an aggressive primary brain neoplasm with dismal prog-
nosis. Based on successful phase III trials, 60 Gy involved-field radiotherapy in 30 fractions
over 6 weeks [Standard radiation therapy (RT)] with concurrent and adjuvant temozolomide
is currently the standard of care. In this disease, age and Karnofsky Performance Status
(KPS) are the most important prognostic factors. For elderly patients, clinical trials com-
paring standard RT with radiotherapy abbreviated to 40 Gy in 15 fractions over 3 weeks
demonstrated similar outcomes, indicating shortened radiotherapy may be an appropriate
option for elderly patients. However, these trials did not include temozolomide chemother-
apy, and included patients with poor KPS, possibly obscuring benefits of more aggressive
treatment for some elderly patients. We conducted a prospective Phase II trial to exam-
ine the efficacy of a hypofractionated radiation course followed by a stereotactic boost
with concurrent and adjuvant temozolomide chemotherapy in elderly patients with good
performance status. In this study, patients 65 years and older with a KPS>70 and his-
tologically confirmed GBM received 40 Gy in 15 fractions with 3D conformal technique
followed by a 1–3 fraction stereotactic boost to the enhancing tumor. All patients also
received concurrent and adjuvant temozolomide. Patients were evaluated 1 month post-
treatment and every 2 months thereafter. Between 2007 and 2010, 20 patients (9 males and
11 females) were enrolled in this study.The median age was 75.4 years (range 65–87 years).
At a median follow-up of 11 months (range 7–32 months), 12 patients progressed and 5 are
alive. The median progression free survival was 11 months and the median overall survival
was 13 months.There was no additional toxicity.These results indicate that elderly patients
with good KPS can achieve outcomes comparable to the current standard of care using an
abbreviated radiotherapy course, radiosurgery boost, and temozolomide.
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INTRODUCTION
Malignant gliomas, including glioblastoma multiforme (GBM) are
the most common primary brain tumors in adults and the age-
adjusted incidence of these high-grade gliomas has increased over
recent years (Lowry et al., 1998; Kohler et al., 2011). Currently
available data extrapolated from retrospective studies or meta-
analysis suggest that performance status is the strongest prognostic
factor in the elderly (Curran et al., 1993; Li et al., 2011). How-
ever, many of these retrospective studies suffer from biased patient
selection and often do not include patients over 65 years of age.
Older patients have a worse survival outcome compared with
younger patients (Ampil et al., 1992; Siker et al., 2011). Recur-
sive partitioning analysis of Radiation Therapy Oncology Group
(RTOG) glioma trials (Curran et al., 1993), the United King-
dom Molecular Research Council (UK MRC), and European
Organization for Research and Treatment of Cancer (EORTC)
prognostic groups have consistently shown that elderly patients
and those with poor performance do poorly. Shortened treatment
time may be advantageous for many elderly patients as it poten-
tially maximizes out-of-hospital time in this disease with limited
prognosis. The National Cancer Institute of Canada (NCIC) con-
ducted a multi institutional randomized controlled study compar-
ing 40 Gy in 15 fractions over 3 weeks to the standard treatment
with 60 Gy in 30 fractions over 6 weeks (Roa et al., 2004). There
was no statistically significant difference between the two arms
in survival or quality of life, and abbreviated radiation therapy
(RT) patients required less steroid therapy. Findings were sim-
ilar in the analysis of the UK MRC Glioma study where there
was no difference in overall survival outcome in the 57 elderly
(>65 years subset) patients who received 45 Gy in 20 fractions
(Bleehen and Stenning, 1991). These trials included many elderly
patients with poor Karnofsky Performance Status (KPS). While
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the shorter course may be suitable for the elderly, patients with
good performance status may benefit from full doses of radiation.
One strategy to deliver higher radiation doses while preserving
an overall abbreviated treatment course is through stereotactic
radiosurgery (SRS).
In early retrospective series the overall median survival of
patients treated with SRS was quite encouraging (Buatti et al.,
1995; Gannett et al., 1995; Masciopinto et al., 1995). Based on
this, the RTOG opened a prospective randomized trial evaluating
up front SRS followed by external beam radiation therapy (EBRT)
with BCNU vs. EBRT and BCNU in 1993 (protocol 93-05). Results
showed no difference in survival outcomes between the study arms
(Souhami et al., 2004). Thus the best current evidence does not
support an advantage for adding SRS to standard doses of radio-
therapy for GBM. However, the benefit of adding SRS to reduced
doses remains an open question.
In the case of elderly patients with GBM, we hypothesized that
the advantages of hypo fractionation (shorter course of radiation
using higher daily doses) could be supplemented by SRS to deliver
total doses of radiation more in line with Standard RT. We also rea-
soned that this dose of radiation when combined with concurrent
and adjuvant Temozolamide could approximate results obtained
with Standard RT and temozolomide as demonstrated in Phase
III randomized trials (Stupp et al., 2005) while preserving the
advantages of a shorter overall treatment course.
MATERIALS AND METHODS
This was an institutional review board approved prospective single
arm phase II study. Patient selection and eligibility criteria required
that all patients have histologically confirmed GBM, be 65 years of
age or older, have a pre-treatment KPS of >70, and not have con-
traindications for radiotherapy or temozolomide. Pathology was
confirmed with surgical resection when deemed feasible; other-
wise a core needle biopsy was obtained. Pre- and post-operative
(when resected) MRI along with baseline blood counts and chem-
istry studies were obtained in all patients. Patients with recurrent
glioma, brainstem invasion, and prior radiation to the head and
neck area were excluded from the study. Protocol therapy was
started within 5 weeks of surgery.
EXTERNAL BEAM RADIATION THERAPY
Patients were simulated in a supine position with a thermoplastic
immobilization head mask. Planning CT scans with IV contrast
were obtained and transferred to the treatment planning sta-
tion. Pre-operative and post-operative MRI scans were utilized
for fusion with simulation CT scans for outlining the target vol-
ume. Fused FLAIR/T2 images were used to contour changes in the
fused axial CT images to delineate the gross tumor volume (GTV).
A 1.5–2 cm expansion was added to the GTV to create the plan-
ning target volume (PTV). Non-coplanar egocentric beams with
appropriate energy and conformal collimation were used. Isodose
distributions, treatment plans, and dose volume histograms were
generated to produce a homogenous plan with less than ±10%
inhomogeneity within the target volume. The prescribed dose to
the PTV was 40 Gy delivered in 15 daily fractions.
STEREOTACTIC RADIOSURGERY
Frameless SRS with the CyberKnife system was used to deliver
the boost. The target volume was determined by changes in the
contrast enhancing T1 MRI. The isodose line covering 95% of
the target volume was used as the prescription. The prescribed
dose depended on the greatest dimension of the lesion. For lesions
less then 2 cm the dose was 22 Gy, for lesions between 2.1 and
3.0 cm the dose was 18 Gy, for lesions between 3.1 and 4.1 cm
the dose was 15 Gy, and for lesions larger than 4.1 a fractionated
regime of 8 Gy× 3 fractions for a total dose of 24 Gy was used. All
patients received anti-edema (dexamethasone) and anti-seizure
(leveteracetam) prophylaxis.
DOSE LIMITATION FOR CRITICAL STRUCTURES
The lens and cervical spine were shielded from the direct beam
during EBRT delivery. When possible, without shielding the gross
tumor, attempts were made to limit the optic chiasm dose to
54 Gy, the retina dose (of at least one, but preferably both eyes)
to 50 Gy, the lens dose to 8 Gy, and the brain stem dose to 60 Gy in
2 Gy/fraction equivalents and inclusive of the radiosurgery boost
dose.
TEMOZOLOMIDE CHEMOTHERAPY
Temozolomide was prescribed orally (75 mg/m2/day) for 4 weeks
during EBRT and during the week of SRS boost therapy.
Chemotherapy began 1 h before the first fraction of EBRT and
continued during weekends and holidays. Four to six weeks after
completion of SRS, Temozolomide (150 mg/m2/day) was pre-
scribed orally for 5 days (days 1–5) of each 28-day cycle. This
schedule was continued without interruption, as long as there was
no tumor progression and toxicity was≤grade 3, for 1 year or until
completion of 28 treatment cycles (whichever was longer).
FOLLOW-UP
All patients were followed with weekly clinical examination
and complete blood counts during treatment. Patients were
then routinely followed every month for blood counts, clinical
assessment, and Temozolamide prescription. Contrast enhanced
Table 1 | Patient and treatment characteristics.
Sex
Male 9
Female 11
Age (>65 years) – mean (range) 75.4 years (65–87 years)
Extent of surgery
Gross total resection 10
Sub total resection 3
Biopsy 7
Karnofsky performance status
70 14
80 2
90 4
100 0
Salvage therapy
Bevacizumab 5
Phase I trial 2
Other systemic therapy 0
Stereotactic radiosurgery 1
No salvage therapy 9
N/A (no progression) 3
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FIGURE 1 | EBRT and CyberKnife SRS treatment plans for a patient who
received 40 Gy in 15 fractions to FLAIR for the first course followed an
SRS boost toT1 Enhancement at a total dose of 24 Gy delivered in 3
fractions. Shown are the (A) axial, (B) sagittal, and (C) coronal views of the
EBRT treatment plans and the (D) axial, (E) sagittal, and (F) coronal views of
the CyberKnife SRS treatment plans.
MRI scans were obtained 1 month after radiation and every
2 months thereafter until progression. Progression was defined
as worsening enhancement in MRI in the setting of neurological
deterioration.
STATISTICAL ANALYSIS
The primary end point of the study is median and 6 month pro-
gression free survival with a secondary end point of overall survival
and tolerability. The study was designed to discern a 50% improve-
ment in progression free survival at 6 months over that reported
in Roa et al. (2004). Calculations indicated that a sample size of 25
patients were required for a single arm phase II study. Descriptive
statistics were used to describe the data. Kaplan–Meier survival
analysis was used for computing progression free and overall
survival with Prism (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
Twenty patients (9 male and 11 female patients) were included
in this study. The mean age was 75.4 years (range 65–87 years).
All patients completed the protocol treatment as prescribed. After
delivery of 40 Gy in 15 fractions for the initial course, three
patients received a single fraction SRS boost. The remaining 17
patients had a target volume exceeding 4 cm in greatest dimen-
sion. These patients received a total SRS boost dose of 24 Gy
delivered in 3 fractions. Table 1 describes the patient and treatment
characteristics. Figure 1 illustrates an EBRT and a SRS treatment
plan.
At a median follow-up of 11 months (range 7–32 months), 11
patients had tumor progression. Four of these patients deterio-
rated neurologically in the absence radiological progression. Two
patients died of unrelated causes (one from untreated sepsis and
the other from a pulmonary embolism from deep venous throm-
bosis). Five patients were still alive at last follow-up. The median
progression free survival was 11 months and the median overall
survival was 13 months (Figure 2). At progression, patients were
offered second line chemotherapy or hospice care.
TOXICITY
All patients tolerated and completed protocol treatment. All
patients experienced fatigue and skin reaction (erythema and
alopecia), not requiring and further treatment (Grade I). Four
patients required prolonged dexamethasone for symptomatic
cerebral edema, which eventually resolved (20% grade II toxicity)
in all but two of the patents. These two patients required hospi-
talization for management. Two additional patients were hospital-
ized: one for urinary tract infection, and the other for pulmonary
embolism. These events were unlikely to be directly related to study
participation. Overall four patients (20%) experienced Grade III
toxicity. There were no life threatening (Grade IV) complications
or treatment related deaths.
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DISCUSSION
The current standard treatment for patients with glioblastoma is
60 Gy of involved-field radiation in 30 fractions delivered over
6 weeks with concurrent and adjuvant Temozolamide. The 6 week
duration of this conventional radiation treatment is not well tol-
erated by the elderly. While lesser doses of radiation have been
shown to be equivalent in the elderly with a wide range in perfor-
mance status, for those patients with a good performance status
(KPS> 70) it is possible that conventional radiation doses may be
more efficacious. Hence hypofractionation (shorter course of radi-
ation with larger doses per fraction) along with a highly conformal
boost could potentially deliver equivalent, but tolerable doses of
radiation in short treatment duration with improved outcome and
quality of life. To date, this study supports that hypothesis with
a median progression free survival of 11 months and a median
overall survival of 13 months.
The elderly population is growing and with it the incidence
of cancer, especially brain tumors, is increasing in the elderly age
group. However, it is unclear whether this increase is a result of
improvements in diagnosis or represents a true increase in the
incidence of cancer (Lowry et al., 1998; Kohler et al., 2011). Older
patients have a worse survival outcome compared with younger
patients. Several hypotheses have been put forward to explain the
poor clinical outcome of elderly patients with brain tumors. The
presence of co-morbidity, resistance to cancer therapy, genetic
aberrations, different histology, neurodegeneration, and age dis-
crimination have all been proposed as reasons why elderly patients
have a poorer outcome compared with younger patients. However,
this does not explain why survival is also reduced in elderly patients
without co-morbidities. Brain tumors in elderly patients seem to
have an intrinsic resistance to treatment. Rosenblum et al. (1982)
observed that sensitivity to carmustine in clonogenic cells from
biopsy specimens was strongly correlated with patient age. Elderly
patients may also develop larger tumors as a result of cerebral
atrophy, which can allow more tumor growth before symptoms
become evident.
In a study of post-operative RT for 301 newly diagnosed
GBM patients, Barker et al. (2001) reported that younger age
(P < 0.006), higher post-operative KPS before RT (P < 0.027),
and more extensive resection (P < 0.028) were strictly correlated
with response to RT, which is known to be a strong predictor of
survival. In one prospective non-randomized study of 79 GBM
patients over 65 years of age who had minimal residual disease,
good performance status (KPS> 60), and received standard of
care treatment, overall median survival was 12.5 months (compa-
rable to other reports in similar groups of patients; Brandes and
Monfardini, 2003; Brandes et al., 2003). This study showed that
for elderly patients, aggressive management with surgical resec-
tion followed by RT (59.4 Gy/33 fractions with limited fields) and
adjuvant temozolomide provided a significant survival advantage
over RT alone (median, 14.9 vs. 11.2 months; P < 0.002). The
randomized NCIC and the MRC trials discussed above favored
a shortened course of radiation for elderly patients, however, the
median overall survival in this trial was diminished when com-
pared to standard of care therapy at 5.1 months for Standard RT
and 5.6 months for abbreviated course RT. The two caveats in
these trials were that many patients likely had a poor KPS and the
FIGURE 2 | Kaplan–Meier analysis of (A) progression free survival and
(B) overall survival.
patients did not receive systemic therapy. Hence it is possible that
in the chemotherapy era those patients with good KPS may benefit
from full doses of radiation.
The 1990s saw published reports on several small series of
patients treated with SRS boost for the primary treatment of
malignant glioma (Buatti et al., 1995; Gannett et al., 1995; Mas-
ciopinto et al., 1995; Kondziolka et al., 1997; Shenouda et al.,
1997; Shrieve et al., 1999; Nwokedi et al., 2002). However, the
results of radiosurgical series were viewed with skepticism (Anker
et al., 2010). In an attempt to reduce bias, many authors sought
out retrospective control populations. One of the largest reviews
attempted to retrospectively stratify 115 patients from three insti-
tutions according to the prognostic classes of the RTOG recursive
partitioning analysis of the patients enrolled on RTOG 74-01, 79-
18, and 82-02 (Sarkaria et al., 1995). This analysis concluded
that there was a significant improvement in both 2 year and
median survival favoring SRS-treated patients. Nevertheless, this
approach, along with all retrospective comparisons, is inherently
flawed. RTOG opened protocol 93-05 in 1993 (Souhami et al.,
2004). This was a prospective randomized trial evaluating upfront
SRS followed by EBRT with BCNU (Arm 1) vs. EBRT and BCNU
(Arm 2). At a median follow-up of 44 months, the median survival
for Arm 1 was 14.1 months (95% CI: 11.0–14.9) and 13.7 months
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Table 2 |Toxicity.
Toxicity Number (%) Grade
Skin erythema 21(100) I
Patchy alopecia 21(100) II
Steroid dependence 2(9.5) II
Cerebral edema (hospitalization) 2(9.5) III
Possibly related (UTI, PE) 2(9.5) III
UTI, urinary tract infection; PE, pulmonary embolism.
(95% CI: 11.3–15.2) for Arm 2 (P = 0.53). The 2-year actuarial
survival rates were 22% for Arm 1 and 16% for Arm 2. There
was no statistically significant difference in the incidence of late
toxicity between the arms. Hence, the current standard ther-
apy remains 6 weeks of radiation (60 Gy) with concurrent and
adjuvant temozolamide (Stupp et al., 2005).
Our trial aimed at achieving the benefit of delivering ade-
quate radiation in a shortened time with concurrent and adju-
vant chemotherapy. The progression free survival in this trial of
11 months compares very favorably to the EORTC/NCIC trial and
to that of prior trials for this disease. This is in spite of our trial’s
designed inclusion of only elderly patients rather than patients of
all ages. This evidence hints that our abbreviated overall course of
treatment is not inferior to standard of care treatment.
The steroid dependency rate in out trial was about 20%. In
two French studies (Marantidou et al., 2010; Carpentier et al.,
2012) with conventional radiation, about 55% of patients required
increasing doses of steroids and 40–100% of patients had persis-
tent requirement of steroids at 3 months depending on extent of
resection. Also in our study steroids were deliberately used as pro-
phylaxis for the stereotactic boost. There was no other excessive
toxicity in our study other than Grade II fatigue, skin erythema,
and alopecia (Table 2).
One theoretical reason for the improved local control, as
reflected in improved progression free survival, could be the deliv-
ery of higher stereotactic radiation dose to the contrast enhance-
ment after initial radiation to the surrounding edema. It has been
hypothesized that treatment resistant glioma stem cells reside in
the areas of enhancement and these may be better treated with
higher doses of radiation in the setting of systemic therapy (Cheng
et al., 2010). This hypothesis remains to be proven.
CONCLUSION
Old age and poor performance status are the two most significant
prognostic factors in patients with Glioblastoma. Elderly patients
tolerate a prolonged course of radiation poorly and those with
good performance status may benefit from aggressive therapy.
Hypofractionated radiation with a stereotactic boost can deliver a
shorter course of adequate radiotherapy effectively and safely in
the temozolamide era.
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APPENDIX
FIGURE A1 |Trial profile.
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